UCLA Invents Newsletter
Newsletter published by: UCLA OIP-ISR December 2013

 IN THIS ISSUE
EVENTS

 Dec. 06, 2013
 
FirstFridays @OIP-ISR
 Theme:  "Partnering with  Industry and Academia"

 Dec. 09, 2013
 
Lunch-N-Learn @OIP-ISR
 Topic:  "Startup Valuation for Faculty Entrepreneurs"

More Events


       


Dear Colleagues
,

As we enter the holiday season, the entire OIP-ISR team would like to express their gratitude to the tremendously talented UCLA research community. It is your creativity and insight that drives innovation across a broad range of markets and industries, delivering impact locally and around the globe.

OIP-ISR has been hard at work facilitating the transfer of UCLA inventions from the lab to the marketplace. In FY2013, UCLA was amongst the top universities in the world in terms of startup creation, new inventions disclosed, industry-sponsored research support, and licensing income.

Inventions increased 14%, and license and option agreements executed increased over 30%. Industry-sponsored research brought over $39 million to support research on campus. Companies are actively developing numerous new products and services based on UCLA technologies in fields such as cancer therapeutics, energy storage, biofuels, and more. All of this is possible because of you.

We wish you all a very happy holiday season and look forward to more world-changing innovation in the years to come!

Sincerely,

Brendan Rauw
Associate Vice Chancellor and
Executive Director of Entrepreneurship


Kinross Bldg 2

UCLA-Industry Partnerships Bring Public Benefit, Boost Innovation 
Increasing partnerships with industry is part of a broader effort to make UCLA more entrepreneurial and speed the translation of research discoveries into products that benefit the public.

Mouse Models:  Valuable to Industry, A Great Source of Income for Research Labs 
UCLA’s OIP-ISR has licensed numerous mouse lines generated by UCLA faculty researchers to companies looking to optimize their R&D dollars.
ImmunGene

UCLA Licensee, ImmunGene, Raises $9 Million in Series A Funding 
ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group.
KytheraBio

UCLA Venture Capital Fund Awards 1st Annual Entrepreneurial Achievement Award 
Keith Leonard, president and CEO of KYTHERA Biopharmaceuticals, Inc., has been presented with the 2013 UCLA VC Fund Entrepreneurial Achievement Award for his outstanding success as a UCLA-affiliated entrepreneur.

 Intellectual Property Announcements


U.S. Patents Awarded

  • 8,580,511 - Two-color fluorescent reporter for alternative pre-mRNA splicing | P. Stoilov, et al.
  • 8,575,319 - Cleavable vaccine compositions and uses thereof and methods . . .| J. Timmerman
  • 8,566,038 - Compositions and methods for analyzing immobilized . . .| J. Gimzewski, et al.
  • 8,563,692 - Interferon-antibody fusion proteins demonstrating potent . . .| S. Morrison, et al.
  • 8,562,892 - Mechanical process for producing particles in a fluid | T. Mason
  • 8,562,795 - Nanoscale electric lithography | Y. Chen
  • 8,552,150 - MART-1 T cell receptors | J. Economou, et al.
  • 8,549,630 - Trojan-resistant bus architecture and methods | J. Villasenor, et al.


New Technologies Available for Licensing
UCLA Invents Newsletter, Vol. 2, No. 4

Subscribe and receive UCLA Invents by email: 
http://oip.ucla.edu/UCLAinvents

Send editorial comments and corrections to:  
Bob Nidever,  bnidever@research.ucla.edu

Contributors: Neil Bajpayee, Ben Dibling

UCLA Invents is published by the Office of Intellectual Property & Industry Sponsored Research
11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu

Copyright 2013 UC Regents




Share this